International Experts Summit on Cardiology and Cardiovascular Research

Blood clotting is one of the body's most carefully balanced biological systems. When a blood vessel is injured, hemostasis helps prevent excessive blood loss. When clot formation occurs inside an intact vessel or becomes unnecessarily extensive, however, the same biological mechanisms can contribute to thrombosis , potentially causing heart attack, stroke, pulmonary embolism, deep-vein thrombosis, or other serious cardiovascular complications. Modern cardiovascular medicine therefore faces a delicate challenge: preventing harmful clot formation without creating excessive bleeding. Advances in thrombosis research, anticoagulant pharmacology, laboratory medicine, and personalized risk assessment are helping clinicians approach this balance with increasing precision. Understanding Hemostasis Hemostasis is the natural process through which the body responds to vascular injury. It involves interactions between blood vessels, platelets, coagulation proteins, and regulatory mechanism...

Cardiovascular treatment does not end when a patient leaves the hospital. For many people recovering from a heart attack, coronary intervention, heart surgery, heart failure, or another cardiovascular condition, the next stage of care can determine how successfully they return to everyday life. Cardiac rehabilitation and lifestyle medicine provide a structured approach to recovery by combining supervised exercise, nutrition, risk-factor management, education, psychological support, and long-term behavior change. Cardiac rehabilitation is a medically supervised program designed to improve cardiovascular health and help patients regain confidence and physical capacity after a cardiac event or diagnosis. Contemporary programs are multidisciplinary and can include physicians, nurses, exercise specialists, dietitians, pharmacists, behavioral-health professionals, and other healthcare providers. Understanding Cardiac Rehabilitation Cardiac rehabilitation is more than an exercise program...

Cardiovascular diseases (CVDs) remain one of the greatest public health challenges of the modern era. They affect people across countries, age groups, and socioeconomic backgrounds, placing pressure not only on individuals and families but also on healthcare systems and national economies. Although many cardiovascular conditions are preventable or manageable, unequal access to prevention, diagnosis, treatment, and long-term care continues to contribute to avoidable illness and death. According to the World Health Organization, an estimated 19.8 million people died from cardiovascular diseases in 2022 , representing approximately 32% of all deaths globally. More than three-quarters of CVD deaths occur in low- and middle-income countries, demonstrating that cardiovascular disease is not only a medical issue but also a major global health-equity challenge. Understanding the Global Cardiovascular Burden Cardiovascular disease encompasses a broad group of conditions affecting the heart a...

Cardiovascular disease has traditionally been viewed as a predominantly male health problem, but this perception does not reflect the full reality. Heart disease remains a major health concern for women, and its risk factors, symptoms, disease progression, and responses to treatment can differ from those commonly observed in men. Understanding these differences is an important step toward improving prevention, diagnosis, treatment, and long-term cardiovascular outcomes for women. Women’s cardiovascular health is influenced by biological, hormonal, metabolic, reproductive, and social factors. Conditions that occur specifically during pregnancy or around menopause can also provide important information about a woman's future cardiovascular risk. As cardiovascular research becomes more inclusive, scientists and clinicians are increasingly recognizing the importance of sex-specific approaches to heart health. Understanding Cardiovascular Risk in Women Many traditional cardiovascular...

The relationship between metabolism and cardiovascular health has become one of the most important areas of modern medical research. Conditions such as obesity, type 2 diabetes, hypertension, abnormal cholesterol levels, fatty liver disease, and chronic kidney disease rarely occur in isolation. Instead, they can interact through shared biological pathways and gradually increase the risk of atherosclerosis, heart failure, coronary artery disease, stroke, and other cardiovascular complications. This interconnected relationship is increasingly described through the concept of cardiovascular-kidney-metabolic (CKM) health . The 2026 AHA/ACC/ADA/ASN guideline provides a unified framework for understanding how metabolic and kidney abnormalities can contribute to cardiovascular disease across the life course. How Metabolic Disorders Affect the Heart Metabolic disorders can influence the cardiovascular system through several interconnected mechanisms. Excess adipose tissue, particularly abdomin...

Cancer treatment has transformed dramatically, allowing millions of patients to live longer after diagnosis. However, as cancer survival improves, increasing attention is being given to the effects that cancer and its treatments can have on the cardiovascular system. This growing field, known as cardio-oncology , brings together oncology and cardiovascular medicine to prevent, identify, and manage heart and vascular complications while allowing patients to receive effective cancer therapy. Cardiovascular complications can develop during cancer treatment or years afterward. They may include heart failure, hypertension, arrhythmias, coronary artery disease, myocarditis, thromboembolic disease, and vascular complications. The European Society of Cardiology's 2022 cardio-oncology guidelines emphasize cardiovascular risk assessment before treatment, monitoring during therapy, and continued surveillance after treatment. Understanding the Heart-Cancer Connection Cancer and cardiovascular ...

Acute coronary syndromes (ACS) represent some of the most time-sensitive conditions encountered in cardiovascular medicine. When blood flow to the heart muscle is suddenly reduced or blocked, irreversible myocardial injury can develop rapidly. For this reason, the recognition, diagnosis, and treatment of ACS depend on coordinated emergency care in which every stage—from the first medical contact to definitive coronary treatment—can influence patient outcomes. ACS includes a spectrum of acute ischemic conditions, particularly ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. Although these conditions differ in their clinical and diagnostic characteristics, they share an underlying problem involving acute disruption of coronary blood flow. Contemporary guidelines increasingly emphasize treating ACS as a continuous clinical spectrum while tailoring treatment according to the patient's presentation and risk...

Cardiovascular medicine has entered an era in which drug development is becoming increasingly precise, data-driven, and biologically targeted. For decades, cardiovascular pharmacology focused on controlling blood pressure, reducing cholesterol, preventing thrombosis, and improving cardiac function. Today, researchers are exploring therapies that act on specific molecular pathways, genetic mechanisms, inflammatory processes, metabolic signals, and disease-related biomarkers. The evolution of cardiovascular pharmacology is important because heart and vascular diseases are biologically diverse. Two patients with the same diagnosis may respond differently to the same medication because of differences in genetics, metabolism, disease stage, kidney function, or other biological factors. Novel drug development therefore aims not only to discover new medicines but also to determine which patients are most likely to benefit from them. The Foundation of Cardiovascular Pharmacology Cardiovascular...